This content is from:APP亚博娱乐
孩子来说治疗计划ns IPO
Clarus Therapeutics is seeking to raise around $60 million from an initial public offering (IPO) by selling five million shares.
Clarus Therapeuticsis seeking to raise around $60 million from an initial public offering (IPO) by selling five million shares,The Wall Street Journalreports. The U.S. maker of an oral testosterone product is planning to list its common stock onNASDAQ Global Market.
Thomas McNerney,who current holds 70.9% of Clarus, will own 51% after the offering, whileHIG Ventureswill own 18% from a previous 25% stake.PiperJaffrayandWellsFargoSecuritieshave been appointed as the lead underwriters for the offering.
Click here for the story fromThe Wall Street Journal.
Click here for additional coverage fromChicago Breaking Business.